

# Quanterix

## Quanterix to Present Poster Session on Blood-based Brain Biomarker Measurements of Sports Related Brain Injury at Neuroscience

**Lexington, Mass. – November 4, 2013** — [Quanterix Corporation](#), a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that they will be attending Neuroscience 2013 on November 9 – 13, 2013 in San Diego, CA. Jeffrey Randall, Ph.D., Principal Scientist at Quanterix, will deliver a poster presentation on a pilot study using its Single Molecule Array ([Simoa](#)) technology that looks at blood biomarkers for sports-related brain injury in collaboration with the Swedish Hockey League.

### Poster Session Details:

#### Plasma Tau Levels in Concussed Hockey Players

Tuesday, November 12, 2013, 2:00 – 3:00 p.m. PT  
San Diego Convention Center, Halls B-H

Convenient biomarker assessment of mild to severe sports-related traumatic brain injury represents a desirable goal as an adjunct for assessing the severity of injury and fitness to return to play. Methods for measuring the brain protein tau in serum and plasma have, until recently, been unavailable. Now, using Quanterix's highly sensitive Simoa measurement of peripheral total tau, Jeffrey Randall, Ph.D. will share insights on the plasma total tau levels in professional hockey players who had suffered a sports-related concussion in a pilot study. Randall will also share post-concussion plasma tau levels that were followed over the course of approximately six days, and how they compared with tau levels in a cohort of hockey players prior to the start of the hockey season.

### Connect with Quanterix at Neuroscience 2013:

For more information on Quanterix and Simoa technology, please visit them at booth #3227 and to learn more about the event, please visit: <http://www.sfn.org/annual-meeting/neuroscience-2013>.

### About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: [www.quanterix.com/simoa-is-here](http://www.quanterix.com/simoa-is-here).

###

### Contacts:

Nikki Festa & Caitlyn Keating  
PAN Communications  
617-502-4300  
[quanterix@pancomm.com](mailto:quanterix@pancomm.com)